Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 298

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 298
---
 grant sublicenses in multiple tiers according to the terms of the Aexon License Agreement. Subject to earlier termination of the Aexon License Agreement in accordance with its terms, the term of the Aexon License Agreement is from the effective date of the Aexon License Agreement to the latest of (i) NLS’s termination of the commercialization of one or more pharmaceutical or therapeutic products, or any combination thereof, in the use of such compounds for narcolepsy and other neuro degenerative disorders in the last region and country in which commercialization had actually begun, and (ii) the expiration of the last -to-expireValid Claim (as defined in the Aexon License Agreement) of a patent identified in the Aexon License Agreement and patents owned by Aexon as of the date of the Aexon License Agreement, that covers such pharmaceutical or therapeutic product for the use of such compounds for narcolepsy and other neuro degenerative disorders in the respective country or region in which it was used. Pursuant to the terms of the Aexon License Agreement, NLS agreed to pay Aexon a royalty on a country -by-countrybasis of 5% to 30% depending on (i) earnings by NLS in a specified region or country for licensed products covered by patents, (ii) whether the applicable patent has not been granted to the applicable product at the time of commercialization of such product and (iii) whether NLS challenges the validity of a patent. NLS must 160 also make payments to Aexon upon the occurrence of certain milestones. Such payments upon the occurrence of milestones contemplated in the Aexon License Agreement range from $100,000 to $300,000. Further, pursuant to the Aexon License Agreement, NLS has agreed to pay Aexon a percentage of license fees, milestones and royalties received from sublicensees. On March 20, 2024, we entered into a securities purchase agreement for the issuance of 175,000 common shares at $10.00 per share in a registered direct offering, which closed on March 22, 2024. Investors also received unregistered warrants to purchase up to 87,500 common shares at $10.00 per share in a concurrent private placement. The warrants were immediately exercisable and expire five years from issuance. The agreement includes customary representations, warranties, and indemnification provisions. We agreed not to issue or announce the issuance of any common shares or equivalents for 45 days post -closing,